myDiagnostic

Genetic tests designed for patients with symptoms or suspicion of hereditary genetic disease.

This product requires extensive patient history. If you are interested fill out the below form. MORE INFORMATION

This product is currently out of stock and unavailable.

SKU: N/A Category:

Description

i

myGenome Diagnostic

Whole Genome Sequencing for patients with a complex medical history or symptoms that suggest a genetic disease and want to know the possible underlying cause.

i

myExome Diagnostic

Whole Exome Sequencing for patients who present symptoms that suggest they may have a genetic disease or have a complex clinical history and want to know the underlying cause that may exist.

I want one of the Diagnostic tests, how can I organize it?

The specialist facilitates the clinical and family history of the patient to the Veritas clinical team.

The patient or legal guardian reads and completes the Informed Consent.

Veritas sequences the sample in the CLIA laboratory.

Veritas sends the specialist a personalized Diagnostic Interpretation report

The specialist prescribes myGenome with Veritas Diagnostic Interpretation.

A blood sample is collected from the patient and sent to Veritas.

An in-depth diagnostic interpretation is made by an expert team, based on the patient’s signs and symptoms.

Additional information

Tipo de test

myGenome Diagnostic

myGenome with Diagnostic Interpretation is a genetic test that uses Whole Genome Sequencing (WGS) and its diagnostic interpretation to help identify diseases suspected of having a genetic origin. Additionally, the test includes information about the response to drugs (Pharmacogenomics) and for adults also the full report of myGenome.

This diagnostic genetic test includes:

  • 2 consultations with a Genetic Counsel A pre-test for the genetic test, where the doctor will deepen your medical history and assess whether the test is suitable for you; and one after the test, in which you will explain the results obtained, its scope and the measures to be adopted.
  • Information about the genetic disease in question (including the 59 genes recommended by the ACMG – American College of Medical Genetics and Genomics).
  • Review of your results by an expert clinical team.
  • Diagnostic interpretation based on clinical signs and symptoms.
  • Information on more than 225 diseases that you can be a carrier, that is, that you can transmit to your children.
  • Information on how your body reacts to more than 300 drugs based on your genetics.
  • Information on more than 50 genetic traits. Grouped in diet and nutrition, longevity, athletics, behavior, cardiovascular health, metabolism and immune system.
  • Encryption, anonymization and high security storage of your genetic information.
  • Ancestry information.

Who is this test for

myGenome with Diagnostic Interpretation is for patients with a complex medical history or symptoms that suggest a genetic disease, even when other genetic tests have been negative. Through the result patients can know variants that explain the symptoms of their disease.

The results may have implications for treatment decisions or prognosis, for medical management options, as well as affect other family members. This test is available for adults (>18 years) and for minors with the consent of the parents.

Complete study

It is highly recommended that the biological samples of the parents are analyzed if they are available, since they can be of help in interpreting the patient’s genomic data. Please note that the analysis of parental samples is included in the price, but a report will not be issued to parents.

In case you want to send samples of other blood relatives, contact us. For the Diagnostic Interpreting Service Veritas collaborates with the Children’s Hospital of Philadelphia, a specialized center with extensive experience in genomic diagnosis, with international prestige.

Technical information

  • Whole Genome Sequencing in illumina HiSeq X10 and NovaSeq 6000 platforms.
  • Veritas complies with the LDT (Laboratory Developed Test) regulation and the test is performed in the CLIA laboratory (CLIA # 22D2089381).
  • The classification of variants is carried out according to the guidelines of the American College of Medical Genetics and Genomics (ACMG).
  • Pathogenic and probably pathogenic variants are confirmed with Sanger sequencing for the diagnostic part of the test. Large deletions and duplications, repeated expansions, certain inversions and deletions, translocations, and large structural rearrangements are not detected.
  • Only inherited variants (germ line), non-somatic variants, mosaicisms or heteroplasmy are detected.

Why Veritas Intercontinental?

Veritas is The Genome Company. Our goal: to make the human genome accessible, so that the specialist can help the patient to maximize the quality and duration of his life and that of his family. As the first company to introduce Whole Genome sequencing and its interpretation for healthy people and their specialists, we maintain the scientific and technological leadership in this field, thus reducing the cost of the genome.

Founded in 2014 by leaders in genomics at Harvard Medical School, Veritas has been recognized twice by MIT Technology Review as one of 50 Smartest Companies in 2016 and 2017, by Fast Company as one of the most innovative healthcare companies and by CNBC as one of the Disruptor 50 Companies in 2018.

myExome Diagnostic

myExome with Diagnostic Interpretation is a genetic test that uses Whole Exome Sequencing (WES) and its diagnostic interpretation to help identify conditions that may a genetic origin.

Who is this test for?

myExome with Diagnostic Interpretation is for patients with a complex medical history or symptoms that suggest a genetic disease, even when other genetic tests have been negative. Through the result patients can know variants that explain the symptoms of their disease. The results may have implications for treatment decisions or prognosis, for medical management options, as well as affect other family members. This test is available for adults (> 18 years) and for minors with the consent of the parents.

Complete study

It is highly recommended that the biological samples of the parents be analyzed if they are available, since they can be of help in interpreting the patient’s genomic data.

For the Diagnostic Interpreting Service Veritas collaborates with the Children’s Hospital of Philadelphia, a specialized center with extensive experience in genomic diagnosis, with international prestige.

 

Technical information

  • Whole Genome Sequencing in illumina HiSeq X10 and NovaSeq 6000 platforms.
  • Veritas complies with the LDT (Laboratory Developed Test) regulation and the test is performed in the CLIA laboratory (CLIA # 22D2089381).
  • The classification of variants is carried out according to the guidelines of the American College of Medical Genetics and Genomics (ACMG).
  • Pathogenic and probably pathogenic variants are confirmed with Sanger sequencing.
  • Large deletions and duplications, repeated expansions, certain inversions and deletions, translocations, and large structural rearrangements are not detected.
  • Only inherited variants (germ line), non-somatic variants, mosaicisms or heteroplasmy are detected.

Why Veritas Intercontinental?

Veritas is The Genome Company. Our goal: to make the human genome accessible, so that the specialist can help the patient to maximize the quality and duration of his life and that of his family. As the first company to introduce complete genome sequencing and its interpretation for healthy people and their specialists, we maintain the scientific and technological leadership in this field, thus reducing the cost of the genome. Founded in 2014 by leaders in genomics at Harvard Medical School, Veritas has been recognized twice by MIT Technology Review as one of 50 Smartest Companies in 2016 and 2017, by Fast Company as one of the most innovative healthcare companies and by CNBC as one of the Disruptor 50 Companies in 2018.

 

What makes the difference?

  • Highly uniform sequencing coverage with spike-in method of additional probes for specific regions.
  • Medium sequencing coverage of 110x and 97% bases covered at> 20x.
  • Detection of variants with a sensitivity and analytical specificity of> 98% and> 99.9% respectively, with a precision of> 99.9%.
  • The test covers more than 19,300 genes, incorporating specific probes to improve the coverage of genes.
  • The classification of the variants is done with a proprietary bioinformatic pipeline, reviewed by our expert clinical team.